PLYX Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026
Revenue
0
0
0
Cost of Revenue
0
0
0
Gross Profit
0
0
0
Operating Expenses
3.3M
+141.2%
1.4M
-29.5%
2.0M
R&D
2.5M
+240.9%
719.0K
+5.9%
679.0K
SG&A
877.0K
+32.7%
661.0K
-48.3%
1.3M
Operating Income
-3328000
-141.2%
-1380000
+29.5%
-1958000
EBITDA
-3328000
-141.2%
-1380000
+29.5%
-1958000
Net Income
-3328000
-141.2%
-1380000
+45.8%
-2544000
EPS (Basic)
$-0.07
-133.3%
$-0.03
+40.0%
$-0.05
EPS (Diluted)
$-0.07
-133.3%
$-0.03
+40.0%
$-0.05
Shares (Diluted)
49.8M
+3.2%
48.3M
+2.2%
47.2M
Polaryx Therapeutics (PLYX) — Financials